NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug ...
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday. Separately, Cantor ...
We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are ...
Small-cap stocks in the US have been under pressure, with the Russell small cap index falling 10% from its November highs as ...